Instron® Launches Next Generation Autoinjector Testing System

Norwood, MA – Instron is excited to announce the release of the next generation Autoinjector Testing System for full functionality testing of pen and autoinjectors to ISO 11608. Developed in close partnership with pharmaceutical companies and CDMOs, this system measures a variety of essential performance requirements, including cap removal, dose accuracy, activation force, injection time, needle depth, and needle guard lockout.

Image Credit: Instron

The ability to perform a complete sequence of tests on one system, rather than multiple systems, simplifies testing, data consolidation, and the validation process, and streamlines tech transfer to production sites.

The addition of simple autoinjector test methods to Instron’s Bluehill Universal software empowers users to easily develop and change test methods. The user simply selects which tests (cap removal, injection, and/or needle guard lock out check or defeat force) are to be run and sets the desired parameters. The system then automatically runs through the test sequence and provides results including cap removal and activation forces, injection time, needle depth measurements at the start and end of injection, click detection, delivered volume, and safety check results.

Image Credit: Instron

“Throughout the development of this system, the user interface and experience has been a major focus,” explains Theresa Smith, Product Manager at Instron. “Our customers in development settings require flexibility as they work with new devices and combined products. With this system, they can easily and quickly change setups to test different devices or perform challenge testing. At the same time, our Bluehill software offers the simplicity and traceability that is needed in production settings. It can be a challenge to design for those very different functions, so this system’s adaptability is really exciting.”

​​​​​​​Bluehill Universal for autoinjectors also improves compliance with Good Manufacturing Practices (GMP) by integrating system suitability testing (SST) into its workflow. SST prompts users to perform daily verification checks on the load cell, machine vision camera, and scale. The system only allows device testing to proceed once these checks have been successfully completed. SST details are recorded in the Traceability module’s audit log, offering a robust and searchable record.

To simplify tech transfer, Instron’s Bluehill Central lab management software can be added to streamline management and transfer of both device and SST test methods between testing systems in the same lab and other sites around the world.

Instron also offers services, including on-site calibrations and IQOQ services, to help testing labs accelerate their validation process.

Autoinjector Testing System | Semi-Automated System for Testing Pen and Autoinjectors to ISO 11608

About Instron

Instron is a leading global manufacturer of testing equipment for the material and structural testing markets used to evaluate materials ranging from biological tissue to advanced high-strength alloys. Instron systems perform a variety of tests such as compression, cyclic, fatigue, impact, multi-axis, rheology, tensile, and torsion. Instron is a wholly owned subsidiary of Illinois Tool Works Inc. For more information, visit



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Instron - USA. (2024, June 12). Instron® Launches Next Generation Autoinjector Testing System. News-Medical. Retrieved on July 25, 2024 from

  • MLA

    Instron - USA. "Instron® Launches Next Generation Autoinjector Testing System". News-Medical. 25 July 2024. <>.

  • Chicago

    Instron - USA. "Instron® Launches Next Generation Autoinjector Testing System". News-Medical. (accessed July 25, 2024).

  • Harvard

    Instron - USA. 2024. Instron® Launches Next Generation Autoinjector Testing System. News-Medical, viewed 25 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.